PlasmaTech Biopharmaceuticals Inc. a biopharmaceutical company develops protein biologic therapies and oncology supportive care products. The company s marketed product comprises MuGard the management of oral mucositis and ProctiGard for the treatment of radiation proctitis a frequent side effect of radiation treatment to the pelvic region. It also develops CobOral a mediated oral delivery technology that utilizes the body s natural vitamin B12 transport system in the gut and CobaCyte a mediated targeted delivery technology that has application in in tumor targeting. The company was formerly known as Access Pharmaceuticals Inc. and changed its name to PlasmaTech Biopharmaceuticals Inc. in October 2014. PlasmaTech Biopharmaceuticals Inc. is based in Dallas Texas.
Fuente:
Reuters. Las cotizaciones tienen una demora de al menos 20 minutos.
- Información diferida en 30 minutos
- Prohibida su reproducción total o parcial